New drug ivonescimab tested for tough cancers
NCT ID NCT06567314
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a drug called ivonescimab in 24 people with advanced cutaneous squamous cell carcinoma (a type of skin cancer) or castration-resistant prostate cancer. The goal is to see if the drug can help control the cancer and to check for side effects. Participants take the drug by mouth, and the study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivonescimab (a drug given by mouth)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced skin cancer and a hard-to-treat type of prostate cancer.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo tame resistant prostate cancer?
- Can a radioactive 'Smart Bomb' shrink resistant prostate tumors?
- Immunotherapy before surgery may cut skin cancer recurrence
- AI could predict which prostate cancers turn aggressive
- Scientists map metabolic shifts in skin cancer development
- Cancer-Killing virus shows promise in early trial for advanced tumors